drugset
drugset / Trial / NCT07557927

A Multicentre, Randomised, Double-blind, Positive-control Clinical Trial Evaluating Dihydroartemisinin Tablets for the Treatment of Discoid Lupus Erythematosus

NCT07557927 ↗

Phase 2 Not yet recruiting 100 enrolled Kunming Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is a multicentre, randomised, double-blind, double-dummy, phase II clinical trial with a positive-control group, designed to evaluate the efficacy and safety of dihydroartemisinin tablets in the treatment of discoid lupus erythematosus (DLE).

Timeline

Start
2026-04-30
Primary completion
2028-09-30
Completion
2028-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject ARTENIMOL Small molecule 40 mg Oral
Subject ARTENIMOL Small molecule 60 mg Oral
Comparator Hydroxychloroquine Small molecule 200 mg Oral

Indications

discoid lupus erythematosus